Professionals 232 Users Online

Antiviral Drugs Market

Market Study on Antiviral Drugs: Swelled demand for broad-spectrum antibiotic drugs to amplify the market

Global Antiviral Drugs Market by Type (Branded and Generics) in DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Neuraminidase Inhibitors Drug Classes

Market Snapshot

Newly-released Antiviral Drugs Market analysis report by Persistence Market Research shows that global sales of the Antiviral Drugs Market in 2022 were held at US$ 63 Billion. With a CAGR of 0.2% during 2023 - 2033, the market growth is projected to reach a valuation of US$ 62.5 Billion. The market through Reverse Transcriptase Inhibitors is projected to remain the key revenue contributor.



Global Antiviral Drugs Market (2022)

US$ 62.7 Million

Global Antiviral Drugs Market (2032)

US$ 64 Billion

Global Antiviral Drugs Market CAGR (2022 – 2032)


U.S. Antiviral Drugs Market CAGR (2022 – 2032)


Key Companies Profiled

  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • AbbVie
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd.
Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Revenue of Antiviral Drugs from 2018 to 2022 Compared to Demand Outlook for 2023 to 2033

As per the Antiviral Drugs Market research by Persistence Market Research - a market research and competitive intelligence provider, historically, from 2018 to 2022, the value of the Antiviral Drugs Market increased at 0.2% CAGR, wherein, countries such as the U.S., China, Japan, the U.K., and South Korea held a significant share in the global market.

The antiviral therapeutics market is expected to grow rapidly, owing to increased antiviral drug research and development spending by both private and public companies from 2023 to 2033.

The sudden emergence of COVID-19 had a positive impact on the growth of the global antiviral therapy market. The key market players including Gilead Sciences, Inc., GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck & Co. Inc. are collaborating on the research and development of new therapies in order to reduce the cost of treating viral infections. For instance, Cipla and Gilead Sciences formed a partnership alliance in May 2020 to develop and commercialize an investigational medicine for the treatment of COVID-19 patients.

The need for broad-spectrum antiviral drugs has increased due to the treatment of novel coronavirus. COVID-19 is commonly treated with Remdesivir, Favipiravir, Oseltamivir, and other combination medicines. In the next two to three years, rising disease incidence combined with increased R&D will drive the demand for antiviral drugs.

In the coming years, increasing collaborations for antiviral drug development and manufacturing are expected to result in the development of a large number of novel drugs. The Antiviral Drugs market is projected to grow at a CAGR of 0.2% over the coming 10 years.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

Reverse Transcriptase Inhibitors segment dominated the market for antiviral drugs and accounted for a significant revenue share in 2022. Check How?

The market through reverse transcriptase inhibitors is projected to remain dominant over the forecast period. One of the key factors for its large share is the increasing diagnosis and treatment rate of HIV, as they are mainly used to treat HIV infection. Furthermore, owing to the presence of reverse transcriptase inhibitors in the pipeline the demand for these drugs will be fuelled in the forthcoming years.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Regional Analysis

Which Region Is expected to Have Significant Growth Potential in The Antiviral Drugs Market?

During the forecast period, the market for antiviral drugs in Asia Pacific is expected to grow at a significant rate. The significant market growth can be attributed to the rising prevalence of viral infections, the transforming healthcare infrastructure, and rising public awareness of infectious diseases in the region.

The expansion of pharmaceutical companies manufacturing generic drugs in countries such as India and China, coupled with the region's growing geriatric population, is driving market growth.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Analysis

U.S. Antiviral Drugs Market Analysis

The US market dominated the Antiviral Drugs Market in 2022, and the market in the country is expected to grow with a CAGR of 0.2% and will touch the market revenue of US$ 21.8 billion by 2033.

The increasing investment in research and development by the key players, as well as the robust drug approval by the United States Food and Drug Administration (FDA) in recent years, have contributed to the market's growth in North America. The key drivers in the United States are an increase in viral infection vaccination rates and government initiatives to reduce the incidence of viral infections. For example, the government in the United States is taking several steps, including investing in infectious disease programs and promoting R&D activities for novel viral infection therapies.

China Antiviral Drugs Market Analysis

The market in China with a CAGR of 0.3% will reach a market valuation of US$ 6 billion by the end of 2033. The market in the country is projected to grow due to the rising geriatric population with a high susceptibility to infections. Furthermore, favorable government policies and initiatives, as well as infrastructural development, are enhancing market growth. Infectious disease prevalence, an increase in hospital-acquired infections, and increased awareness of treatment therapies are driving the demand for antiviral drugs in China.

China is developing antiviral drugs based on three main strategies to combat SARS-CoV-2. The first strategy aims to stop the virus from replicating, while the second aims to prevent the virus from entering a target cell. The third strategy is to control the immune system's extreme reaction.

Japan Antiviral Drugs Market Analysis

In Japan, the market is expected to reach a valuation of US$ 2.3 billion by 2032, growing at a CAGR of 0.3% during 2022 – 2032.

South Korea Antiviral Drugs Market Analysis

The market in South Korea is expected to register a CAGR of 0.2% during the forecast period to reach a valuation of US$ 1.4 billion by 2032. The market during this period is projected to witness an absolute dollar opportunity of US$ 28 million.

Category-wise Insights

Why branded Antiviral Drugs dominate the Market?

Branded antiviral drugs are expected to maintain their dominance in the market. The segment is expected to be driven by the high adoption rate in the North American and European markets.

The generics segment is being driven by rising demand for generic antiviral drugs in developing countries due to their cost-effectiveness. The market for generic antiviral drugs is very competitive and price-sensitive.

HIV Application Dominates the Antiviral Drugs Market. Check How?

The market is expected to grow at a faster rate due to the high prevalence of HIV infection combined with a high treatment rate, the presence of branded drugs, and government initiatives to increase the treatment rate. The governments in key countries have announced the Ending the HIV Epidemic (EHE) plan, which aims to end the HIV epidemic in the near future. The goal of the initiative is to reduce HIV infections and improve diagnosis and treatment rates all over the world.

Competitive Analysis

The way in which competition is dealt with has changed considerably as competition has increased. The key companies in the Antiviral Drugs market include Gilead Sciences, Inc., GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., AbbVie Inc., and Merck & Co. Inc.

Some of the recent developments in the Antiviral Drugs Market are as follows:

  • In May 2022, Cipla limited partnered with Genes2Me Pvt. Ltd. for the commercialization of an RT-Direct multiplex RT PCR kit for Covid-19. It is targeted to increase its diagnostics portfolio.
  • In March 2022, Scripps Research, partnered with AbbVie Inc. to examine a novel, immediate antiviral treatment for COVID-19.
  • In January 2020, Florida State University (FSU) announced to open new doors for innovative treatment options for more than 36 million HIV-positive people globally. The new treatment options would also aid in the treatment of chronically ill hepatitis B patients.
  • In October 2020, Veklury (Remdesivir), the first drug approved to treat Covid-19, was approved by the US Food and Drug Administration (FDA) for use in adults and pediatric patients aged 12 and up who weigh at least 40 kg (88 pounds) and require hospitalization.

Market Segments Covered in Antiviral Drugs Market Analysis

By Drug Class

  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Other Drug Classes

By Type

  • Branded
  • Generics

By Application

  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Other Applications

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

- Companies Covered in This Report -

  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc
  • AbbVie
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd.

- Frequently Asked Questions -

The global Antiviral Drugs Market is worth US$ 63 Billion at present.

The market value is projected to increase at a CAGR of around 0.2% during 2023 – 2033.

The market value increased at a CAGR of around 0.2% during 2018 – 2022.

Branded antiviral drugs are estimated to account for a significant value share in 2023.

Over the period 2023-2033, the market in the market in Asia Pacific is expected to grow at a significant rate.

The top five countries driving demand for Antiviral Drugs are the U.S., U.K., Japan, China, and South Korea.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate